This clinical photograph comparison presents six views of facial hair growth in a study involving identical twins to evaluate the efficacy of topical minoxidil. The images are divided into two rows: (a) shows the treatment subject after 16 months of daily 5% minoxidil foam application, and (b) shows the non-treated control subject. Both individuals are photographed 10 days post-shave. Row (a) demonstrates a significantly higher follicular density, increased hair shaft thickness, and more extensive terminal hair coverage across the beard, mustache, and cheek regions. In contrast, row (b) exhibits sparser, finer, and patchier hair distribution. The comparison highlights the pharmacological effect of minoxidil on prolonging the anagen phase and increasing follicular size in androgen-sensitive facial areas. Key anatomical focuses include the submandibular region, malar area, and perioral region. This visual is intended for dermatological education regarding hair loss treatments and off-label uses of minoxidil for facial hair enhancement.

An anatomical diagram illustrating the targeted delivery of minoxidil (MXD) into hair follicles using three different pharmaceutical formulations: MXD microparticles (MXD-MPs), MXD nanoparticles (MXD-NPs), and a commercially available MXD solution (CA-MXD). The diagram depicts a cross-section of human skin, including the stratum corneum, epidermis, and dermis, featuring a central hair follicle with labeled regions for the hair bulge and bulb. Visual coding shows: 1) MXD-MPs (blue) resulting in low drug concentration at the hair bulge and significant accumulation at the stratum corneum; 2) MXD-NPs (pink/red) demonstrating high concentration and deep penetration into the hair bulge, where hair follicle stem cells (lavender spheres) are located; and 3) CA-MXD (teal) showing middle-range concentration levels. The illustration emphasizes the follicular delivery pathway, suggesting that nanoparticle-based formulations facilitate superior drug accumulation in the bulge region, which is critical for activating epithelial stem cells and promoting hair growth, while potentially minimizing systemic absorption through the stratum corneum.

This composite educational image details the use of a FRET-based sensor, KIRIN1, to monitor intracellular potassium (K+) concentrations during zebrafish pectoral fin bud development. Panels A and B explain the mechanism of Fluorescence Lifetime Imaging Microscopy (FLIM), where increased K+ leads to a reduced donor fluorophore lifetime (shorter ns). Panels D-F provide quantitative data showing a significant transient increase in intracellular K+ (as 1/lifetime) in both the ectoderm and mesenchyme peaking around 48 hours post-fertilization (hpf), correlating with rapid fin bud growth. Panels G-I display pseudocolored FLIM z-stacks at 32, 48, and 56 hpf; at 48 hpf, a shift toward red/yellow hues signifies higher K+ levels compared to the blue/green hues at 32 and 56 hpf. Panels J-M investigate the role of the K+ channel kcnk5b using mosaic transgene expression. Confocal planes (Ka, La) and corresponding FLIM images (Kb, Lb) illustrate that cells expressing kcnk5b-mCherry exhibit lower 1/lifetime values, indicating reduced intracellular K+ compared to wild-type neighbors, confirming the channel's functional role in modulating ionic concentration during morphogenesis.

Clinical photograph (top view) demonstrating the scalp of a 31-year-old female with androgenetic alopecia (AGA), showing side-by-side 'before' and 'after' results following five platelet-rich plasma (PRP) treatment sessions over 4 months. The 'before' image illustrates a classic female pattern of hair loss, characterized by significant diffuse thinning across the central scalp, crown, and vertex, with a widened part line and high visibility of the underlying scalp. The hair strands appear fine and miniaturized. The 'after' image demonstrates clinical improvement, evidenced by increased hair density and follicular volume. There is a noticeable narrowing of the central part line and enhanced coverage of the scalp surface. This comparison highlights the efficacy of PRP as a therapeutic modality for non-scarring alopecia, illustrating its role in stimulating hair regrowth and improving hair shaft thickness in patients with hormonally-mediated hair loss.

Clinical photograph showing a side-by-side comparison of the vertex and mid-scalp of a 46-year-old female patient with female pattern hair loss (androgenetic alopecia). The 'before' image (left) demonstrates diffuse thinning, characterized by a widened central part and increased scalp visibility, consistent with a Ludwig scale classification of hair loss. The 'after' image (right) displays the clinical outcome three months following three sessions of platelet-rich plasma (PRP) therapy. Visually, the 'after' state shows a significant increase in hair density, a narrowing of the central part line, and improved scalp coverage. The medical specialty is dermatology, focusing on trichology and non-surgical hair restoration. This comparison serves as an educational resource to illustrate the therapeutic potential of PRP in managing follicular miniaturization and increasing hair volume in patients with androgenetic alopecia.

This clinical comparison photograph illustrates the progression of hair growth in a patient with androgenetic alopecia (AGA) before and after therapy. The 'Before treatment' image shows a superior view of the scalp, highlighting significant hair thinning and reduced follicular density primarily at the vertex and mid-scalp regions, resulting in high scalp visibility. The second image, taken 'One month following the first treatment' with Botulinum Toxin Type A (BTA), demonstrates a visible increase in hair density and coverage. The previously exposed patch of scalp is noticeably smaller and less prominent, suggesting improved terminal hair count and follicle activation. This visual evidence supports the clinical application of BTA to improve local blood flow and oxygenation in the scalp to counteract the effects of dihydrotestosterone (DHT) and hypoxia in AGA patients. The comparison serves as an educational tool for evaluating dermatological treatment efficacy for male pattern baldness.